Market Overview

UPDATE: Canaccord Genuity Upgrades InterMune to Buy on Esbriet EU Momentum

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

Canaccord Genuity raised its rating on InterMune (NASDAQ: ITMN) from Hold to Buy and increased its price target from $11 to $13.

Canaccord Genuity commented, "We've been waiting for a signal that ITMN could execute on marketing Esbriet – we think this could be it. We think the strength in Q3 sales may signal the start of a new ramp in pirfenidone sales, buoyed by upcoming French and Italian launches. We expect continued positive momentum in H1/13 as France and Italy could be better organized and more enthusiastic re pirfenidone than Germany. We are raising our target on increased adoption rates forecast in Q4/12, 2013 and 2014."

InterMune closed at $8.16 on Wednesday.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!